HPV Infection–Associated Cancers: Next-Generation Technology for Diagnosis and Treatment

Cornelia L. Trimble

Abstract

Disease caused by human papillomavirus (HPV) remains common, despite preventive vaccines and screening strategies. Globally, HPVs cause one third of infection-associated cancers. The indolent clinical course of the precursor intraepithelial lesions provides an opportunity to understand immunologic obstacles posed by the microenvironment of incipient disease, and how they might be overcome. Results from recent therapeutic HPV vaccine clinical trials suggest that relevant immune responses may be sequestered at the lesion site and are difficult to detect in the circulation. In this Cancer Immunology at the Crossroads article, we outline the current understanding of the risk, diagnosis, and treatment of HPV infection–associated cancers and suggest that quantitative tissue–based endpoints should be included whenever possible in the evaluation of immune-based therapies. Cancer Immunol Res; 2(10); 937–42. ©2014 AACR.

Introduction

On a global scale, approximately one in six new cancer diagnoses is attributable to an infectious pathogen (1, 2). Malignancies caused by human papillomaviruses (HPV) comprise one third of infection-associated cancers, including cancers of the cervix, vagina, vulva, anus, and oropharynx. Today, despite the existence of strategies to either detect or prevent cervical HPV disease, cervical cancers cause 7.5% of cancer-related deaths in women (3). Because these cervical neoplastic lesions are relatively accessible, and non-self antigens are required for disease, these lesions present an opportunity to increase our understanding of the mechanisms governing immune responses in the cervical mucosa. Developing immune therapies for disease caused by HPV is important because existing strategies for the early detection and prevention of disease are both cumbersome and expensive, and therefore HPV disease remains common. In the United States, the annual cost of HPV disease per birth cohort of girls is estimated to be over $6.5 billion (Table 1; refs. 3–7).

In part, the expense of preventing HPV disease reflects our incomplete understanding of the risk of disease. Most people are exposed to HPVs shortly after the onset of sexual activity, and most of these people clear their infection without intervention and without being aware that they have been infected (8, 9). In unvaccinated persons, the lifetime risk of infection at least once with an oncogenic HPV type is estimated to be 80% (10). Our relatively recent ability to test routine clinical specimens obtained at the time of cervical screening for the presence of oncogenic strains of HPV has presented the clinical conundrum of how to identify early HPV lesions that present a true risk for cancer. Fewer than one third of women referred for colposcopic evaluation of an abnormal Pap smear or a positive HPV test have confirmed disease that requires treatment (11). No screening algorithms have been validated for HPV disease of the oropharynx, penis, anus, vulva, or vagina. The incidence of HPV-associated malignancies in these anatomic sites for which screening strategies have not yet been validated continues to increase, particularly in the oropharynx (12). Although the currently available prophylactic vaccines provide protection against HPV16, the genotype most commonly associated with HPV malignancies, to date, uptake has been uneven. Because HPV exposure occurs with the onset of sexual activity, and because the currently available prophylactic vaccines have no therapeutic effect, it is likely that HPV infections will continue to contribute to the global burden of disease for the foreseeable future.

Immune Therapies for HPV Disease

Both squamous cervical cancers (SCCx) and their immediate precursor lesion, cervical intraepithelial neoplasia 2/3 (CIN2/3), are associated with integration of the viral genome into the host genome, and subsequent functionally obligate, constitutive expression of two viral gene products, E6 and E7 (13, 14). Expression of both E6 and E7 is required, but not sufficient, for initiation and persistence of the disease. Because CIN lesions are both accessible and clinically indolent, they present an opportunity to explicate mechanisms of immune-mediated clearance of disease.

The need for objective, quantitative methods for tissue studies can be illustrated by the history of immune therapies for HPV disease. To date, although much has been learned about the immunobiology of HPV disease, and preclinical models demonstrate therapeutic efficacy of E6- and E7-specific
T cells against solid tumors expressing these antigens, in humans, therapeutic vaccinations targeting the E6 and E7 antigens have yielded limited success. Although E6 and E7 are not “self” antigens, they have shown limited immunogenicity in peripheral blood lymphocytes in the vectors tested to date. Several recent publications, however, suggest that peripheral vaccination can indeed induce immune responses in target lesions. Two trials of therapeutic vaccination in subjects with vulvar intraepithelial neoplasia (VIN) have reported rates of complete regression (CR) that were approximately 10-fold higher than what would be expected without intervention (15, 16). Untreated, the rate of spontaneous regression of VIN lesions is less than 5% (17). One trial tested vaccination with long peptides spanning the length of E6 and E7, administered intramuscularly with incomplete Freund’s adjuvant, in subjects with HPV16-positive high-grade VIN (16). This trial reported a 47% CR rate. Another trial tested vaccination with fusion protein (L2E6E7) in sequence with imiquimod, a topical Toll-like receptor (TLR) 7/8 agonist, applied to the lesion (15). These investigators reported a CR rate of 63%. In both trials, an immune response provoked by the immunologic intervention had effect on the lesions, including peripheral blood T-cell responses to vaccine antigens; although the responses were detectable, they required several days of ex vivo expansion for detection. The design of these trials differed from canonical phase I trials in that the 52-week time period between the initial trial intervention and the time of the histologic endpoint was far longer than most other trials. These trials suggest that it takes time for an immune response to be effective, even in a host with only intraepithelial disease, and that relevant immune responses may be recruited to the site of antigen, not lingering in the peripheral blood.

Indeed, recently, we reported evidence of striking changes in target tissues after therapeutic vaccination, in subjects with HPV16+ CIN2/3 (18). Seven weeks after vaccination with a heterologous DNA prime-recombinant vaccinia virus vector-based boost regimen, although immune responses to vaccine antigens in the blood were increased only modestly, we found lymphoid aggregates composed of proliferating, clonally expanded CD8 T cells that localized specifically in residual dysplastic mucosa in subjects who had residual disease. Intralesional CD8+ infiltrates were increased in residual lesions, which also showed evidence of squamous cell apoptosis. These findings were congruent with the clinical regressions obtained in the VIN clinical trials, suggesting that in the case of immune therapies for intraepithelial HPV disease, the indolent clinical behavior of these lesions permits a longer period of observation after treatment that would allow an immune response to eliminate the disease. They also demonstrate the value of including tissue endpoints before and after immunotherapeutic interventions, if at all possible.

### Tissue-Resident Immune Cells

Until relatively recently, much of our understanding of the kinetics, functional polarization, lineage commitment, and homeostasis of immune cells has been derived from studies performed on either peripheral blood or splenic lymphocytes. In an adult human, most antigen-experienced T cells reside in peripheral tissues, most of which are nonsterile barrier epithelia (19–21). A growing body of literature attests to the concept of tissue tropism of immune memory cells. Most infectious pathogens have a pronounced and specific tropism for a specific tissue site; memory T cells are tropic for the tissue in which they encountered their cognate antigen. Tissue-resident T cells have been described now in many peripheral tissues, including the skin, lung, gastrointestinal tract, central nervous system, liver, and the lower female genital tract (20). The mechanisms governing the recruitment, functional polarization, potential for functional plasticity, homeostasis, and retention of tissue-resident T cells in humans are only now beginning to be understood.

Tissue analyses of clinical specimens are limited by the small absolute size of tissue, which becomes available only after pathologic diagnosis. The development of sophisticated, high-throughput analytic technologies now provides opportunities to derive a great deal of information directly ex vivo from limited specimens of unmanipulated cells. These studies hold great promise for enhancing our understanding of mechanisms of immune-cell recruitment, repertoire, functional polarization, and cell retention, which must be informed and guided meticulously by tissue image analyses to minimize the odds of deriving heterogeneous data that could obscure or mask a dynamic clinical picture. Although isolation of segregated cell subsets in the epithelial or stromal compartments is time consuming, these kinds of studies will provide insights about interactions between cell types involved in specific histologic contexts. Studies of unmanipulated cells obtained directly from tissue specimens are likely to provide very different insights about mechanisms of immune activation, retention, and homeostasis in the periphery than those that are known from experiments using circulating lymphocytes.

### Quantitative Digital Image Analysis of Lesions

In HPV-associated disease, all squamous cancers are thought to arise from untreated high-grade squamous intraepithelial lesions. However, in the cervix, not all CIN2/3 lesions progress to invasive cancer. We and others have reported that

---

**Table 1. Annual cost of HPV-associated disease for one birth cohort of girls**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cost (in billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical cancer screening</td>
<td>$5,740,000,000</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>$350,000,000</td>
</tr>
<tr>
<td>Other anogenital cancers</td>
<td>$127,000,000</td>
</tr>
<tr>
<td>Oropharyngeal cancer</td>
<td>$38,000,000</td>
</tr>
<tr>
<td>Anogenital warts</td>
<td>$220,000,000</td>
</tr>
<tr>
<td>Respiratory papillomatisis</td>
<td>$151,000,000</td>
</tr>
<tr>
<td>Total</td>
<td>&gt;$6.5 billion</td>
</tr>
</tbody>
</table>

*NOTE: Cost of vaccinating one birth cohort of girls: ~$1 billion ($500/girl × 2 million girls).

²Routine screening accounts for ~63% of the cost; follow-up accounts for the other 37%.
in a time frame of 4 to 6 months, approximately 35% of the CIN2/3 lesions undergo spontaneous regression (22, 23). CIN2/3 lesions caused by monoinfection with HPV16 are less likely to regress (20%–30%). Although regression is mediated presumably by an adaptive immune response, peripheral blood T-cell responses to E6 and E7 are modest, require ex vivo manipulation to be detected, and do not distinguish persons whose lesions regress. This observation raises the question of whether it is possible to identify immune responses in the target lesion that could predict either disease outcome or the likelihood of a clinical response to immune manipulation.

In fact, the intensity of CD8\(^+\) T-cell infiltrates in dysplastic cervical epithelium does predict clinical outcome. A prospective cohort study of low-grade squamous intraepithelial lesions (CIN1) reported an association between the intensity of intraepithelial granzyme B\(^+\)/CD8\(^+\) cells and subsequent regression (24). CIN2/3 lesions in which CD8\(^+\) T-cell infiltrates gain access to dysplastic epithelium are more likely to undergo regression than lesions in which the T-cell infiltrates are restricted to the stroma subjacent to the dysplastic epithelium (25). In contrast, in CIN2/3 lesions that do not regress, CD8 T-cell infiltrates are restricted to the stroma, failing to infiltrate the dysplastic epithelium. This observation is common to many human solid tumors.

The presence of tertiary lymphoid structures in the stroma abutting primary cancers is associated with better prognosis with conventional anticancer treatment modalities in many tumor settings (26–30). Whether these structures comprise tumor-specific effector cells, or whether they arise from tissue-resident immune cells or are composed of cells recruited from the periphery is not yet well understood. Tertiary lymphoid structures are also observed in autoimmune diseases, such as rheumatoid arthritis, and in many chronic inflammatory conditions, such as inflammatory bowel disease. The question of whether primary immune responses can be generated and maintained in peripheral tissues is of central importance to the fields of autoimmunity and tumor immunology.

One approach to tissue analyses involves using quantitative digital image analysis to inform high-throughput molecular studies on single-cell populations. The intensity and colocalization of immune-cell infiltrates of interest can be quantified objectively on a tissue section, using immunohistochemical or immunofluorescence staining and digital image analysis. For example, one could identify regions of interest precisely and distinctly, including the neoplastic epithelium and the immediate subjacent stroma, and the normal epithelium and the stroma immediately subjacent. While immunohistochemical staining can be performed with two colors on a given tissue section, it is now possible to perform multiplex immunofluorescence staining on a single tissue section for as many as six or seven molecular analytes of interest. The intensity and distribution of the different fluoros can be deconvoluted to determine spatial relationships, for example, between intratumoral (epithelial) CD8\(^+\) infiltrates and tissue macrophages in the adjacent stroma. This kind of information can be layered with antibodies that detect changes in methylation, or apoptotic markers, or markers that reflect immune activation, such as PD-L1. This approach is very similar to the idea of flow-

<p>| Table 2. Image analysis–guided molecular profiling of cell subsets in the tumor microenvironment |
|---------------------------------|---------------------------------|---------------------------------|</p>
<table>
<thead>
<tr>
<th>Specimen type</th>
<th>Method</th>
<th>Analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formalin-fixed paraffin embedded tissue (FFPE)</td>
<td>Digital image analysis (bright-field or multiplex immunofluorescence)</td>
<td>Quantify intensity, distribution, and colocalization of molecular analytes of interest</td>
</tr>
<tr>
<td>FFPE or flash-frozen tissue</td>
<td>Immuno-laser-capture microdissection (tissue compartments, individual cells, or individual structures)</td>
<td>TCR deep sequencing, clonal analysis, epigenetic profiling, mRNA transcriptomes</td>
</tr>
<tr>
<td>Primary tissue explants</td>
<td>Isolate viable T cells</td>
<td>Phenotyping, single-cell TCR sequencing, functional polarization</td>
</tr>
<tr>
<td></td>
<td>Isolate passage 1 fibroblasts</td>
<td></td>
</tr>
<tr>
<td>Endocervical cytobrush specimens</td>
<td>Isolate viable T cells from longitudinally obtained specimens: Single-cell toolbox: microengraving, imaging</td>
<td>Phenotyping, cytokine kinetics, RNA-Seq, FISH</td>
</tr>
<tr>
<td>Peripheral blood (PBMC and plasma)</td>
<td>ELISPOT, intracellular cytokine staining, flow cytometry</td>
<td>Quantify antigen-specific response</td>
</tr>
<tr>
<td></td>
<td>Exosome signature</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: PBMC, peripheral blood mononuclear cell; TCR, T-cell receptor.
cytometry phenotyping of individual cells, except that tissue-based studies provide a histologic context. These quantitative measures can be performed on longitudinally obtained tissue specimens from individual subjects, or in cross-sectional studies to identify histologic configurations that are associated with prognosis or that could be used to monitor effects of an intervention.

**Single-Cell Laser-Capture Microdissection**

Unlike circulating lymphocytes, tissue-resident lymphocytes have undergone fewer replicative cycles and are thought to have greater potential for functional plasticity (31). The contributions of stromal cell subsets to lesion persistence or progression are also incompletely understood. The use of high-throughput technologies applied to human tissue specimens, to date, has relied on a "grind-and-find" approach. Now, the availability of laser-capture microdissection microscopes that are capable of isolating single cells has opened the door to performing in-depth studies of unmanipulated tissue-resident cell populations. Rapid immunohistochemical staining can be performed on cryosections to identify specific cell populations of interest. Using pattern-recognition software, the stained cells can be identified readily and isolated directly into PCR tubes for molecular analyses. Although labor-intensive and painstaking, these types of studies will provide data derived from specifically chosen cell subsets in specific histologic contexts (Table 2).

**Clinical Trials: Intelligent Design**

One mechanism by which invasive solid tumors evade effector immune cells is by developing neovascularature that does not express adhesion molecules that mediate egress from the circulation into the tissue. In the clinical setting of cervical HPV disease, high-grade cervical intraepithelial neoplasia can be identified visually using relatively simple technology. A dilute acetic acid wash is applied to the cervix (3% vinegar). Dysplastic cells have a higher nuclear-to-cytoplasmic ratio than do normal cells, and thus dehydrate more readily when exposed to vinegar. When viewed through a low-magnification lens, through a green filter, these dehydrated cells appear white ("aceto-white"). In addition to aceto-white changes, high-grade lesions are also identified by a pathognomonic pattern of neovascularure, termed "mosaicism" (Fig. 1). Cervical T cells express the $\alpha_4\beta_7$ homing integrin. It is now clear that, similar to invasive tumors, one mechanism by which CIN2/3 can prevent recruited effector cells from accessing dysplastic epithelium is because the neovascularure in persistent CIN2/3 has downregulated the expression of MAdCAM, the ligand for $\alpha_4\beta_7$ (25). This finding underscores the need to activate...
lesional vascular endothelium, as a therapeutic goal, in combination with other immunotherapeutic modalities.

Modulating the Lesion Microenvironment Directly

Finally, intraepithelial lesions present an opportunity to learn what is happening with the immune response in either persistent infection or in the early stages of development of intraepithelial lesions. It is also possible to manipulate the lesion microenvironment directly, for example, with topical TLR agonists. Studies have suggested several mechanisms by which this intervention, applied concurrently, might potentiate an effector cell response. Huang and colleagues demonstrated that in cutaneous squamous cancers, imiquimod appeared to potentiate recruitment of effector cells from the periphery into the epithelial compartment of the lesions, and that this was associated with tumor apoptosis and regression (32). Cutaneous squamous cancers evade recruited effector cells by downregulating the expression of the adhesion molecule, e-selectin, a ligand that supports the entry of CLA$^+$ T cells into both normal and inflamed skin (33). Topical imiquimod upregulated the expression of e-selectin and was associated with an influx of CD8$^+$ T cells expressing the skin-homing integrin CLA. TNFα also induced the expression of e-selectin on skin microvessels. TLR agonists have also been shown, in some settings, to mediate tumor apoptosis directly (34). Indeed, in a murine model, investigators have demonstrated that peripheral vaccination with HPV16 E7 long peptides, followed by intravaginal imiquimod, increased by 5-fold the infiltration of vaccine-induced CD8$^+$ T cells in the vaginal mucosa (35). Currently, our group is conducting a clinical trial in which patients with HPV16$^+$ CIN2/3 undergo peripheral therapeutic vaccination with a heterologous DNA prime-recombinant vaccinia (TA-HPV) boost regimen, and they also receive imiquimod, applied directly to the cervix (NCT00788164).

The Beginning of the End of CIN2/3?

In the end, because preinvasive cervical HPV disease is accessible, tissue-based analyses can provide insights into immunologic obstacles posed by the microenvironment of incipient disease and how they might be overcome. Tissue studies in human HPV disease have already identified some barriers in CIN2/3 that are now a therapeutic target in concert with vaccination. Studies of either regressing or persistent lesions can provide unique insights into how the microenvironment of a developing tumor affects the host’s ability to successfully or unsuccessfully address the nascent tumor.

Intraepithelial lesions associated with HPVs are clinically indolent, and are also directly accessible—two features that could allow for making clinical management decisions based on tissue monitoring. Because colposcopically directed biopsies are much less invasive or destructive than a cone resection, patients whose lesional biopsies showed evidence of an effector immune response could potentially be monitored and saved from more invasive surgery, whereas patients whose lesions did not manifest an effector response could proceed to therapeutic resection. These kinds of treatment management decisions will be predicated on a better understanding of what constitutes a clinically meaningful tissue immune response.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This study was supported by grants R01 CA142691 (to C.L. Trimble, PI), 1R21CA123876 (to C.L. Trimble, PI), 2 P50 CA098252 (C.L. Trimble, Project 3 PI), and 5P30-CA09734-48 (Clinical Staff Investigator).

Received August 15, 2014; accepted August 22, 2014; published online October 3, 2014.

References


HPV Infection–Associated Cancers: Next-Generation Technology for Diagnosis and Treatment

Cornelia L. Trimble


Updated version
Access the most recent version of this article at:
http://cancerimmunolres.aacrjournals.org/content/2/10/937

Cited articles
This article cites 35 articles. 8 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/2/10/937.full.html#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
/content/2/10/937.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.